<DOC>
	<DOCNO>NCT00331149</DOCNO>
	<brief_summary>This study design compare effectiveness tolerability new prolonged release formulation ropinirole currently market immediate release formulation prescribe many country . The new prolonged release formulation allow drug take day rather three time day . This study also evaluate side effect new prolonged release formulation ropinirole</brief_summary>
	<brief_title>A Comparison Ropinirole Immediate Release With Ropinirole Prolonged Release Patients With Advanced Parkinson 's</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Ropinirole</mesh_term>
	<criteria>Inclusion criterion : Patients diagnosis advance idiopathic Parkinson 's disease ( accord modify Hoehn &amp; Yahr criterion Stages IIIV ) whose symptom adequately control Ldopa . Exclusion criterion : Patients late stage advance Parkinson 's disease incapacitating dyskinesia stable dose Ldopa . Current , history , ( within previous 3 month ) , significant and/or uncontrolled psychiatric , haematological , renal , hepatic , endocrinological , neurological , cardiovascular disease active malignancy . Recent history severe dizziness faint stand . Dementia , neurotic behaviour , cripple degenerative arthritis limb amputation , prior current major psychosis . Recent history current evidence drug abuse alcoholism . Use dopamine agonist within 4 week start study . Personal family history allergic reaction ropinirole .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>safety</keyword>
	<keyword>efficacy</keyword>
	<keyword>L-dopa</keyword>
	<keyword>ropinirole PR</keyword>
	<keyword>Parkinson 's disease</keyword>
	<keyword>ropinirole IR</keyword>
	<keyword>adjunctive therapy</keyword>
	<keyword>superiority</keyword>
	<keyword>REQUIP</keyword>
	<keyword>health outcome</keyword>
</DOC>